Wegovy vs Zepbound: Brand Name Comparison

Introduction

Wegovy® and Zepbound® are the two FDA-approved brand-name obesity medications dominating the market in 2026. Wegovy (semaglutide 2.4 mg, Novo Nordisk) was approved in 2021. Zepbound (tirzepatide, Eli Lilly) was approved in 2023. Together they’ve reshaped how obesity is treated.

The two drugs use different molecules with different mechanisms, produce different amounts of weight loss, and have different FDA-approved indications beyond obesity itself. Comparing them isn’t just a matter of which is “better” in the abstract. It depends on your specific health profile and what you’re optimizing for.

This guide walks through every important comparison: weight loss data, FDA labels, cardiovascular and other outcomes, side effects, dosing, cost, and the practical experience of being on each drug.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What’s in Each Drug?

Wegovy contains semaglutide at 2.4 mg per weekly dose. Semaglutide is a single agonist of the GLP-1 receptor. It mimics the gut hormone glucagon-like peptide 1, slowing gastric emptying, increasing satiety, improving insulin secretion, and reducing food reward.

Quick Answer: Wegovy (semaglutide 2.4 mg) produced 14.9% weight loss at 68 weeks in STEP 1 (Wilding et al. 2021 NEJM)

Zepbound contains tirzepatide at doses ranging from 2.5 mg to 15 mg per weekly dose. Tirzepatide is a dual agonist of the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual activation produces stronger weight loss than single GLP-1 agonism alone.

Both come as weekly subcutaneous injections. Both require dose escalation. Both are approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

Which Produces More Weight Loss?

Zepbound wins. The SURMOUNT-5 trial (Aronne et al. 2024 NEJM) tested both head-to-head in 751 adults with obesity over 72 weeks. Mean weight loss was 20.2% on tirzepatide 15 mg vs 13.7% on semaglutide 2.4 mg. The proportion losing at least 25% of body weight was 31.6% on tirzepatide vs 16.1% on semaglutide.

In separate major trials, the gap was similar: STEP 1 (Wegovy) at 14.9% vs SURMOUNT-1 (Zepbound) at 20.9%. The data is consistent across independent and head-to-head trials.

For raw weight loss outcome, Zepbound is the higher-performing drug by about 6 to 7 percentage points on average.

What Are the FDA-approved Indications?

The two drugs have different label expansions beyond core obesity.

Wegovy (semaglutide 2.4 mg) is approved for:

• Chronic weight management in adults (2021)
• Chronic weight management in adolescents 12+ (2022)
• Reduction in risk of cardiovascular death, nonfatal MI, and nonfatal stroke in adults with obesity or overweight plus established CVD (2024, based on SELECT trial)

Zepbound (tirzepatide) is approved for:

• Chronic weight management in adults (2023)
• Treatment of moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024, based on SURMOUNT-OSA)

For patients with established cardiovascular disease, Wegovy has the on-label indication backed by SELECT trial data showing 20% MACE reduction. For patients with moderate-to-severe sleep apnea, Zepbound has the only FDA-approved label for that indication.

What About Other Outcome Data?

Wegovy/semaglutide has the deeper outcome trial portfolio in 2026. SELECT (Lincoff et al. 2023 NEJM) showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with overweight/obesity plus CVD over 3.3 years. FLOW (Perkovic et al. 2024 NEJM) showed a 24% reduction in kidney/CV death in diabetic kidney disease. STEP-HFpEF showed benefits in heart failure with preserved ejection fraction.

Zepbound/tirzepatide has SURMOUNT-OSA for sleep apnea. The SURPASS-CVOT cardiovascular outcome trial in type 2 diabetes is ongoing. Additional outcome trials in obesity-related conditions are in progress.

For comorbidities like established CVD or diabetic kidney disease, Wegovy has the stronger evidence base in 2026. For sleep apnea, Zepbound does.

How Do They Titrate?

Wegovy titrates over 16 weeks: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, stepping up every 4 weeks.

Zepbound titrates over 20 weeks: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, stepping up every 4 weeks.

Both require slow dose escalation to manage GI side effects. Zepbound has more dose options between starter and top dose, which sometimes lets patients stop at an intermediate dose if they have a strong response and don’t need to push higher.

Key Takeaway: SURMOUNT-5 head-to-head (Aronne et al. 2024 NEJM) showed Zepbound beat Wegovy 20.2% vs 13.7%

Side Effect Profile

Both have similar GI side effect profiles. Nausea, vomiting, diarrhea, and constipation are the most common adverse events on both drugs, mostly during dose escalation. In SURMOUNT-5 head-to-head, GI side effect rates were similar between Wegovy and Zepbound, with discontinuation for adverse events at 8.0% on Wegovy and 6.1% on Zepbound.

Both have boxed warnings for medullary thyroid C-cell tumor risk based on rodent data. Both can cause gallbladder issues during rapid weight loss. Both have rare reports of pancreatitis. Both can cause modest heart rate increase (2 to 5 bpm) and blood pressure decrease (4 to 6 mmHg systolic).

Individual tolerability varies considerably. Some patients tolerate one but not the other.

What Does Each Cost?

Wegovy list price: approximately $1,349/month. Novo Nordisk’s NovoCare direct cash program offers Wegovy at $499/month for single-dose vials at certain pharmacies, requiring patients to be uninsured or to opt out of insurance for the purchase.

Zepbound list price: approximately $1,086/month. Eli Lilly’s LillyDirect cash program offers Zepbound vials at $349 to $499/month depending on dose, available to uninsured patients or those whose insurance doesn’t cover the drug.

Compounded semaglutide and tirzepatide through telehealth platforms like TrimRx typically run $200 to $500/month, though the FDA’s removal of both drugs from the shortage list (semaglutide in February 2025, tirzepatide in late 2024) has restricted compounding eligibility for many patients.

How Do They Look as Products?

Wegovy comes as a prefilled single-use pen injector. Each pen is one dose. Five different pens are used across the titration schedule (one per dose strength). The injection mechanism is automated; the patient presses the pen against the skin and the device delivers the dose.

Zepbound is available as both prefilled single-dose pens and single-dose vials. The pen is similar to Wegovy in concept. The vials require drawing the dose into a separate syringe, which is more steps but cheaper through Lilly’s direct program.

Both are injected subcutaneously in the abdomen, thigh, or upper arm. Both are stored refrigerated.

Which Is Right for You?

For patients with established cardiovascular disease, Wegovy has the FDA-approved cardiovascular indication and stronger CV outcome data. For patients with moderate-to-severe sleep apnea, Zepbound has the FDA-approved OSA indication. For patients optimizing raw weight loss, Zepbound’s data is stronger.

For patients with type 2 diabetes plus obesity, both are options; the diabetes brand counterparts (Ozempic® and Mounjaro®) are also relevant. For patients with diabetic kidney disease, semaglutide (and therefore Wegovy) has the FLOW trial data.

For patients with no specific comorbidity driving the choice, Zepbound’s stronger weight loss data makes it the first choice for many clinicians, with Wegovy as the alternative if Zepbound isn’t tolerated, accessible, or appropriate.

TrimRx’s free assessment quiz screens eligibility for compounded semaglutide and compounded tirzepatide and matches qualified patients to a personalized treatment plan.

Bottom line: Wegovy list: ~$1,349/month; Zepbound list: ~$1,086/month; both have direct cash programs at $349 to $499/month

FAQ

Can I Switch From Wegovy to Zepbound?

Yes, switching is common when weight loss plateaus on Wegovy or when stronger results are desired. Most clinicians stop Wegovy and start Zepbound at a dose higher than 2.5 mg (often 5 or 7.5 mg) if the patient was at full Wegovy dose, then titrate from there based on tolerance.

Does Insurance Cover Wegovy or Zepbound?

Coverage varies. Many insurance plans require step therapy or prior authorization. Some plans cover only the diabetes versions (Ozempic, Mounjaro) and not the obesity versions. Coverage is changing as employers and PBMs respond to the demand and cost of these medications.

Why Is Zepbound Cheaper Than Wegovy at List?

Eli Lilly priced Zepbound at a deliberate discount to Wegovy at launch. The list price differential is roughly $263/month. Lilly’s direct cash program through LillyDirect is also priced lower than Novo Nordisk’s NovoCare program.

Are Wegovy and Zepbound Interchangeable?

No. They contain different active ingredients (semaglutide vs tirzepatide) with different receptors targeted (GLP-1 only vs GLP-1 plus GIP). They produce different amounts of weight loss and have different FDA-approved indications. Switching between them isn’t a one-to-one swap.

Can I Take Both Wegovy and Zepbound Together?

No. Both target the GLP-1 receptor, and combining them would just stack side effects without adding meaningful efficacy. Patients use one or the other.

Will I Regain Weight If I Stop?

Yes, both drugs show consistent regain when stopped. STEP 4 (Rubino et al. 2021 JAMA) showed semaglutide patients who switched to placebo regained 6.9% by week 68. SURMOUNT-4 (Aronne et al. 2024 JAMA) showed tirzepatide patients regained 14% over 52 weeks after stopping. Both drugs are designed for chronic use.

Are There Generic Versions of Wegovy or Zepbound?

No FDA-approved generics exist. Both drugs are still under patent protection. Compounded versions of semaglutide and tirzepatide are a different legal category, available through certain compounding pharmacies under specific FDA rules, with eligibility now more restricted after the drugs were removed from the shortage list.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.